Cost-effectiveness of initial adherence to antiretroviral therapy among HIV infected patients in Belo Horizonte, Brazil;Análisis coste-efectividad de la adhesión inicial a la terapia antirretroviral entre individuos infectados por el VIH en Belo Horizonte, Brasil

Revista Espanola de Salud Publica

Volumn 80, Issue 1, 2006, Pages 41-54

  Acurcio, Francisco De Assis ^a,d   Puig Junoy, Jaume ^b   Bonolo, Palmira De Fátima ^a,b,c   Ceccato, Maria Das Graças Braga ^a   Guimarães, Mark Drew Crosland ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b UNIVERSITAT POMPEU FABRA   (Spain)

^c Beca   (New Zealand)

^d Saude de Belo Horizonte Beca: CAPES Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior ^*  (Brazil)

Author keywords

Aids; Antiretroviral therapy; Brazil; Cost effectiveness; Economic evaluation; HIV

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ARTICLE; BRAZIL; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FEMALE; HEALTH CARE COST; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRESCRIPTION; SYMPTOMATOLOGY; COMPARATIVE STUDY; COST; DRUG COST; ECONOMICS; HUMAN IMMUNODEFICIENCY VIRUS 1;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BRAZIL; COSTS AND COST ANALYSIS; DRUG COSTS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; PATIENT COMPLIANCE;

EID: 33646088600     PISSN: 11355727     EISSN: 11355727     Source Type: Journal    
DOI: 10.1590/s1135-57272006000100005     Document Type: Article

References (40)

1. Joint United Nations Programme on HIV/AIDS. AIDS epidemic update - December 2004 [capturado en 19/05/2005]. Se consigue en: http://www.unaids.org/ wad2004/report.html
2. News in brief. Fighting AIDS is best use of money, says cost-benefit analysis. Nature 2004; 429:592.
3. Brasil. Coordenação Nacional de DST e Aids. Resposta +: Atenção às pessoas que vivem com HIV e Aids. Brasília: Ministério da Saúde; 2005. [capturado en 09/08/2005]. Se consigue en: http://www.aids.gov.br/final/biblioteca/resposta/ resposta_2005.pdf.
4. Brasil. Coordenação Nacional de DST e Aids. Aids Números apontam estabilização de novos casos. Brasília: Ministério da Saúde; 2003. [capturado en 04/12/2003]. Se consigue en: http://www.aids.gov.br/imprensa/NoticiasImpressao. asp?NOTCod=52007
5. Yasdanpanah Y. Costes associated with combination antiretroviral therapy in HIV infected patients. J Antimicrob Chemother 2004; 53:558-61.
6. Mannheimer S, Friedland G, Matts J, Child C, Chesney M. The consistency of adherence to antiretroviral theraphy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin Infec Dis. 2002; 34:1115-21.
7. Metha S, Moore RD, Graham NMH. Potential factors affecting adherence with HIV therapy. AIDS 1997; 11:1665-70.
8. Poppa A, Davidson O, Deutsch J, Godfrey D, Fisher M, Head S et al. British HIV Association (BHI-VA)/British Association for Sexual Health and HIV (BASHH) guidelines on provision of adherence support to individuals receiving antiretroviral therapy (2003). HIV Med. 2004; 5 Suppl 2:46-60.
9. Chesney MA. Factors affecting adherence to antiretroviral therapy. Clin Infect Dis 2000; 30 Suppl 2:171-6.
10. Nemes MIB. Aderência ao tratamento por antiretrovirais em serviços públicos de saúde no Estado de São Paulo. Brasília: Ministério da Saúde, 2000. 172 p.
11. Goldie SJ, Paltiel D, Weinstein MC, Losina E, Seage GR, Kimmel AD et al. Projecting the cost-effectiveness of aherence interventions in persons with human immunodeficiency virus infection. Am J Med 2003; 115:632-41.
12. Ceccato MGB, Acurcio FA, Bonolo PF, Rocha GM, Guimarães MD. Compreensão de informações relativas ao tratamento anti-retroviral entre indivíduos infectados pelo HIV. Cad Saúde Pública 2004; 20:1388-97.
13. Brasil. Coordenação Nacional de DST e Aids. Recomendações para a terapia anti-retroviral em adultos e adolescentes infectados pelo HIV-2004. Brasília: Ministério da Saúde; 2003. [capturado en 03/12/2003]. Disponible en: htpp://www.aids.gov.br/final/biblioteca/adultos_2004/consenso.doc
14. Brasil. Coordenação Nacional de DST e Aids. Boletim Epidemiológico Aids e DST - Ano I n.01-Janeiro a Junho de 2004. Brasília: Ministério da Saúde; 2005.[capturado en 19/05/2005]. Disponible en: http://www.aids.gov.br/final/dados/BOLETIM2.pdf
15. Bonolo PF, Cesar CC, Acurcio FA, Ceccato MGB, Pádua CAM, Guimarães MDC et al. Non-adherence among patients initiating antiretroviral therapy: a challenge for health professionals in Brazil. AIDS 2005; 19 (suppl 4): S 5-13.
16. Krentz HB, Auld MC, Gill MJ. The high cost of medical care for patients who present late (CD4<200 cels/μL) with HIV infection. HIV Med 2004; 5:93-8.
17. Freedberg KA, Losina E, Weinstein MC, Paltiel AD, Cohen CJ, Seage GR et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med 2001; 344:824-31.
18. Schackman BR, Freedberg KA, Weinstein MC, Sax PE, Losina E, Zhang H et al. Cost-effectiveness implications of the timing of antiretroviral therapy in HIV-infected adults. Arch Intern Med 2002; 162:2478-86.
19. Mauskopf J, Kitahata M, Kauf T, Richter A, Tolson J. HIV antiretroviral treatment: early versus later. J Acquir Immune Defic Syndr 2005; 39:562-9.
20. Holmberg SD, Palella FJ, Lichtenstein KA, Havlir DV. The case for earlier treatment of HIV infection. Clin Infect Dis 2004; 39:1699-704.
21. Acurcio FA, Guimarães MDC. Uso de los servicios de salud y progresión al sida entre personas con infección por el VIH en Belo Horizonte (MG), Brasil. Rev Panam Salud Publica 1998; 4:331-40.
22. Acurcio FA, César CC, Guimarães MDC. Health care utilization and survival among patients with AIDS in Belo Horizonte (MG), Brasil. Reports in Public Health 1998; 14: 801-20.
23. Chequer P, Cuchi P, Mazin R, Garcia Calleja JM. Access to antiretroviral treatment in Latin American countries and the Caribbean. AIDS 2002; 16 Suppl 3:S50-7.
24. Tramarin A, Campostrini S, Postma MJ, Calleri G, Tolley K, Parise N et al. A multicentre study of patient survival, disability, quality of life and cost of care: among patients with AIDS in northern Italy. Pharmaco Economics 2004; 22:43-53.
25. Lopez-Bastida J, Serrano-Aguilar P, Oliva J, Perestelo L. Direct and indirect costs in ambulatory patients living with HIV/Aids in Spain. Proceedings of the IHEA 5th World Congress; 2005 Jul 10-13; Barcelona, Spain. Barcelona: UPF; 2005. p.327.
26. Bartlett JA, Johnson J, Herrera G et al. Initial therapy with abacavir + lamivudine (ABC+3TC) combined with efavirenz (NNRTI), amprenavir/ritonavir (IP), or stavudine (NRTI): ESS40001 (CLASS). Proceedings of the XV International AIDS Conference; 2004 Jul 11-16; Bangkok, Thailand. Bangkok: 2004. Abstract TuPeB4544.
27. Van Leeuwen R, Katlama C, Murphy RL et al. Estudo atlantic: a randomized trial to study firstline combination therapy with or without a protease inhibitor in HIV-1-infected patients. AIDS 2003;17:987-99.
28. Podzamczer D, Ferrer E, Consiglio E et al. Estudo combine: a randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naïve patients (The combine study). Antiviral Ther 2002; 7:81-90.
29. Cooper D, Yeni P. Virological and immunological outcomes at 3 years following initiation of ART with regimens containing a NNRTI or PI or both: The INITIO trial. Proceedings of the 12th Conference on Retroviruses and Opportunistic Infections; 2005 Feb 22-25; Boston, USA. Boston; 2005. Abstract 165LB
30. Bautista S, Mane A, Bertozzi S. The economic impact of choice of antiretroviral therapy in the context of rapid scalling up access to treatment: Lessons from Mexico. Proceedings of the IHEA 5th World Congress; 2005 Jul 10-13; Barcelona, Spain. Barcelona: UPF; 2005. p.162.
31. Garcia de Olalla P, Knobel H, Carmona A, Guelar A, Lopez-Colomes JL, Cayla JA. Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. J Acquir Immune Defic Syndr 2002; 30:105-10.
32. Valenti WM. Treatment adherence improves outcomes and manages costs. AIDS Read 2001; 11:77-80.
33. Basuyau F, Josset V, Merle V, Czernichow P. Case fatality and health care costs in HIV-infected patients: evolution from 1992 to 2000 at Rouen University Hospital, France. Int J STD AIDS 2004;15:679-84.
34. Beck EJ, Mandalia S, Gaudreault M, Brewer C, Zowall H, Gilmore N et al. The cost-effectiveness of highly active antiretroviral therapy, Canada 1991-2001. Aids 2004; 18:2411-8.
35. Anis AH, Guh D, Hogg RS, Wang XH, Yip B, Craib KJ et al. The cost effectiveness of antiretroviral regimens for the treatment of HIV/AIDS. Pharmaco Economics 2000; 18:393-404.
36. Krentz HB, Auld MC, Gill MJ, HIV Economic Study Group. The changing direct costs of medical care for patients with HIV/AIDS, 1995-2001. CMAJ 2003;169:106-10.
37. Wallace MR, Tasker SA, Shinohara YT, Hill HE, Chapman GD, Miller LK. The changing economics of HIV care. AIDS Patient Care STDS 2001;15:25-9.
38. Phair JP, Bozzette SA. The economics of HIV in the HAART era. [citado el 23/08/2005]. Disponible en: http://clinicaloptions.com/hiv/treatment/pe/
39. Sendi P, Palmer AJ, Gafni A, Battegay M. Highly active antiretroviral therapy: pharmacoeconomic issues in the management of HIV infection. Pharmaco Economics 2001; 19:709-13.
40. Supakankunti S, Tsunekawa K, Phetnoi W. Costing of the national access to antiretroviral program for people living with HIV and AIDS in Thailand. Proceedings of the IHEA 5th World Congress; 2005 Jul 10-13; Barcelona, Spain. Barcelona: UPF; 2005. p.217.